Wegovy vs Mounjaro is one of the most common questions people ask when considering medical treatment for obesity and weight management. Both are once-weekly injectable medicines that can significantly reduce body weight, improve metabolic health and help control appetite. However, they are not the same medication.
Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, which acts on both GIP and GLP-1 receptors.
So, which is better: Wegovy or Mounjaro?
The answer depends on the individual patient. Tirzepatide has demonstrated greater average weight loss than semaglutide in a direct head-to-head trial. However, semaglutide has specific cardiovascular outcome evidence and may be particularly relevant for certain patients with established cardiovascular disease.
At Collagen Clinics, Jaipur, treatment decisions should be individualized after considering BMI, diabetes status, cardiovascular health, medications, medical history, treatment goals and potential side effects.
Wegovy vs Mounjaro: Quick Comparison
| Feature | Wegovy | Mounjaro |
|---|---|---|
| Generic name | Semaglutide | Tirzepatide |
| Main mechanism | GLP-1 receptor agonist | GIP + GLP-1 receptor agonist |
| Administration | Once weekly injection | Once weekly injection |
| Main role | Chronic weight management | Type 2 diabetes and, in India, chronic weight management |
| Effect on appetite | Reduces appetite and food intake | Reduces appetite and food intake |
| Average weight loss | Significant | Generally greater than semaglutide in head-to-head obesity trial |
| Cardiovascular outcome evidence | Strong evidence in selected patients with established CVD and overweight/obesity | Cardiovascular evidence is developing |
| Common side effects | Nausea, vomiting, diarrhea, constipation and other GI symptoms | Nausea, vomiting, diarrhea, constipation and other GI symptoms |
In India, Mounjaro (tirzepatide) has been approved for adults with obesity or overweight with a weight-related comorbidity, as well as type 2 diabetes. Wegovy (semaglutide) is also approved for chronic weight management in appropriate adults.
What Is Wegovy?
Wegovy contains semaglutide, a medication belonging to the GLP-1 receptor agonist class.
GLP-1 is an incretin hormone involved in appetite regulation, insulin secretion and glucose metabolism. Semaglutide can reduce appetite, increase feelings of fullness and decrease food intake.
Wegovy is used along with a reduced-calorie diet and increased physical activity as part of long-term weight management.
The approved Indian prescribing information includes adults with a BMI of 30 kg/m² or greater, or adults with a BMI of 27 kg/m² or greater when at least one weight-related health condition is present.
What Is Mounjaro?
Mounjaro contains tirzepatide.
Unlike semaglutide, tirzepatide activates two hormone pathways:
- GIP receptor
- GLP-1 receptor
This is why tirzepatide is often described as a dual GIP and GLP-1 receptor agonist.
Tirzepatide affects appetite, food intake, insulin sensitivity, glucose regulation and gastric emptying. In India, Mounjaro is approved for type 2 diabetes and chronic weight management in appropriate adults with obesity or overweight plus a weight-related comorbidity.
The Main Difference Between Wegovy & Mounjaro
The simplest way to understand the difference is:
Wegovy = GLP-1 receptor agonist
Mounjaro = GIP + GLP-1 receptor agonist
Both medications influence appetite and metabolic pathways, but tirzepatide acts on two incretin pathways rather than one.
This difference may partly explain why tirzepatide has produced greater average weight loss in several clinical studies.
However, a medication should not be selected only because it produces the largest number on the weighing scale.
The patient’s overall medical profile matters.
Which Causes More Weight Loss: Wegovy or Mounjaro?
This is one of the most important differences between the two medicines.
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, directly compared tirzepatide with semaglutide in adults with obesity who did not have type 2 diabetes.
After 72 weeks, the average weight reduction was approximately:
- Tirzepatide: 20.2%
- Semaglutide: 13.7%
Tirzepatide also produced greater average reduction in waist circumference.
Therefore, when the primary goal is maximum average weight reduction, current head-to-head evidence generally favours tirzepatide.
However, individual responses vary considerably. A patient may respond very well to semaglutide and poorly tolerate tirzepatide, or vice versa.
Is Mounjaro Better Than Wegovy?
It is more accurate to say:
Mounjaro may produce greater average weight loss, but it is not automatically the better medication for every patient.
The decision should consider the reason for treatment.
For example, a patient whose major goal is substantial weight reduction may be a good candidate for tirzepatide if there are no contraindications.
On the other hand, a patient with established cardiovascular disease and obesity may have a particularly strong reason to consider semaglutide because cardiovascular outcome data are available for semaglutide in this population.
In the SELECT trial, semaglutide reduced the risk of major cardiovascular events by approximately 20% in adults with established cardiovascular disease and overweight or obesity who did not have diabetes.
Which Patients May Prefer Mounjaro?
Tirzepatide may be particularly attractive in patients where substantial weight reduction and metabolic improvement are major treatment goals.
A doctor may consider tirzepatide in patients with:
1. Obesity requiring significant weight reduction
Patients with significant obesity who need substantial weight loss may benefit from the greater average weight reduction demonstrated with tirzepatide.
2. Type 2 diabetes with overweight or obesity
Tirzepatide has strong glucose-lowering effects in addition to its effects on body weight.
Clinical trials in people with type 2 diabetes have demonstrated substantial reductions in both HbA1c and body weight.
3. Metabolic complications
Patients with obesity accompanied by insulin resistance, type 2 diabetes or other metabolic risk factors may be considered for tirzepatide when clinically appropriate.
4. Patients who have not achieved sufficient weight loss with another approach
A doctor may consider changing treatment when lifestyle measures alone or another medication has not produced adequate results.
The choice should still be individualized rather than based solely on weight-loss percentages from clinical trials.
Which Patients May Prefer Wegovy?
Wegovy can also be an excellent option for appropriate patients.
1. Patients with established cardiovascular disease
This is an important consideration.
Semaglutide has demonstrated cardiovascular benefit in adults with established cardiovascular disease and overweight or obesity without diabetes.
Therefore, in an appropriate patient with this profile, semaglutide may have an important advantage because of its established cardiovascular outcome evidence.
2. Patients who respond well to semaglutide
Not every patient needs the medication producing the highest average weight loss in a trial.
If a patient achieves meaningful weight reduction, good appetite control and acceptable tolerability with semaglutide, there may be no reason to change simply because another medicine has a higher average efficacy.
3. Patients for whom the overall clinical profile favours semaglutide
The choice may depend on cardiovascular history, previous treatment response, side effects, cost, availability and other medications.
Wegovy vs Mounjaro: Side Effects
Both medications can cause gastrointestinal side effects.
Common effects include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Reduced appetite
- Indigestion
These symptoms are often more noticeable when the dose is increased.
For this reason, these medicines are generally started at a lower dose and gradually increased according to the prescribed schedule and patient tolerance.
The goal is not to reach the highest dose as quickly as possible.
Good treatment means finding the dose that provides an appropriate balance between benefit and tolerability.
Can Wegovy & Mounjaro Be Used Together?
No.
Wegovy and Mounjaro should not be combined.
Both affect incretin pathways, and combining them is not a standard treatment strategy. Patients should also avoid independently combining these medicines with other GLP-1 receptor agonists or weight-loss medications without medical supervision.
The Indian Wegovy prescribing information specifically states that semaglutide should not be co-administered with another semaglutide-containing product or another GLP-1 receptor agonist.
Who Should Not Take Wegovy or Mounjaro?
These medicines are prescription treatments and are not suitable for everyone.
A doctor should review the patient’s medical history before treatment.
Particular caution or contraindications may apply in patients with certain:
- Thyroid conditions
- Gastrointestinal disorders
- Pancreatic conditions
- Gallbladder problems
- Kidney problems
- Pregnancy or plans for pregnancy
- Previous serious reactions to these medicines
Both semaglutide and tirzepatide carry important warnings concerning thyroid C-cell tumors based on animal studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 under their respective prescribing information.
Therefore, these medications should never be started simply because they are popular for weight loss.
Wegovy vs Mounjaro for PCOS
Obesity and insulin resistance are common concerns in some women with PCOS.
Weight management can be an important part of PCOS treatment when excess weight is present.
However, neither Wegovy nor Mounjaro should be considered a universal treatment for PCOS.
The decision may depend on:
- BMI
- Insulin resistance
- Type 2 diabetes or prediabetes
- Menstrual symptoms
- Fertility plans
- Other medications
- Cardiometabolic risk
Women who are planning pregnancy should discuss weight-loss medication with their doctor before starting treatment.
Wegovy vs Mounjaro: Which Is Better for Diabetes?
Both medicines can have important metabolic effects, but tirzepatide has demonstrated particularly strong glucose-lowering efficacy in type 2 diabetes.
Mounjaro is approved for the treatment of type 2 diabetes in India, while its Indian approval also includes chronic weight management.
For a patient with type 2 diabetes and obesity, tirzepatide may therefore be an attractive option when clinically appropriate.
However, diabetes treatment should be individualized based on HbA1c, other medications, cardiovascular and kidney health, hypoglycemia risk and treatment goals.
What About Weight Regain After Stopping?
Wegovy and Mounjaro should not be viewed as short-term “slimming injections.”
Obesity is a chronic, relapsing disease.
When effective weight-loss medications are discontinued, appetite may increase and some weight regain can occur.
Therefore, treatment should be considered as part of a long-term weight-management strategy that includes:
- Nutrition
- Physical activity
- Adequate protein intake
- Sleep
- Behavioural changes
- Monitoring of metabolic health
- Appropriate long-term medical treatment
Stopping medication should be discussed with the treating doctor rather than done independently.
Wegovy vs Mounjaro: Which One Should You Choose?
There is no single answer that applies to everyone.
A simplified approach is:
Mounjaro may be preferred when:
- Greater average weight loss is a major goal
- The patient has obesity with type 2 diabetes
- Significant metabolic improvement is required
- The patient tolerates tirzepatide well
Wegovy may be preferred when:
- The patient has established cardiovascular disease and overweight/obesity
- Semaglutide has previously worked well and is well tolerated
- The overall clinical profile favours semaglutide
- Cardiovascular outcome evidence is an important part of the treatment decision
These are general principles, not rules. The final choice should always be made after an individual medical assessment.
Wegovy vs Mounjaro: The Bottom Line
Both Wegovy and Mounjaro are effective prescription medications for weight management, but they work through different mechanisms.
Wegovy contains semaglutide and acts primarily through the GLP-1 receptor. Mounjaro contains tirzepatide and activates both GIP and GLP-1 receptors.
Current head-to-head evidence shows that tirzepatide produces greater average weight loss than semaglutide in adults with obesity without diabetes.
However, “more weight loss” does not automatically mean “better for every patient.”
Semaglutide has important cardiovascular outcome evidence in people with established cardiovascular disease and overweight or obesity, while tirzepatide may be particularly attractive when substantial weight loss and metabolic improvement are major goals.
At Collagen Clinics, Jaipur, the appropriate treatment should be selected after assessing your BMI, medical history, metabolic health, medications, treatment goals and potential contraindications.
Do not start Wegovy, Mounjaro or any other prescription weight-loss medication without medical supervision.
Frequently Asked Questions
Is Mounjaro stronger than Wegovy for weight loss?
Current head-to-head evidence suggests that tirzepatide produces greater average weight loss than semaglutide. In SURMOUNT-5, average weight loss at 72 weeks was 20.2% with tirzepatide versus 13.7% with semaglutide. Individual results can vary.
Can I switch from Wegovy to Mounjaro?
A doctor may consider switching between these medications in selected patients, particularly when there is inadequate response or tolerability issues. The switch and dosing schedule should be medically supervised.
Which is better for diabetes: Wegovy or Mounjaro?
Tirzepatide has strong evidence for glucose lowering and is approved for type 2 diabetes. However, the best treatment depends on the patient’s overall diabetes and cardiovascular profile.
Which is better for PCOS?
Neither medication should automatically be considered the best treatment for PCOS. In women with PCOS and obesity, a doctor may consider anti-obesity medication as part of an individualized treatment plan.
Are Wegovy and Mounjaro safe?
Both have established safety profiles when appropriately prescribed, but they can cause side effects and are not suitable for everyone. A medical assessment is important before starting treatment.
Can I take Wegovy or Mounjaro just to lose a few kilograms?
These are prescription medicines intended for specific medical indications. They should not be used simply for cosmetic weight loss without assessing whether the patient meets appropriate treatment criteria.
Does Mounjaro cause more weight loss than Wegovy?
On average, yes. The 72-week SURMOUNT-5 head-to-head trial found greater weight reduction with tirzepatide than semaglutide.
Medical Disclaimer
This article is intended for general educational purposes and should not replace a consultation with a qualified doctor. Wegovy and Mounjaro are prescription medicines and should only be used after appropriate medical assessment. Individual treatment decisions depend on medical history, examination, BMI, laboratory results, other medications and treatment goals.